Searched for
BIOCON PARK
Kiran Mazumdar-Shaw shares drone cleaning video, asks startups: 'Where's your innovation?'Kiran Mazumdar-Shaw, Biocon founder, sparked debate by questioning startup innovation. She shared a video of a drone cleaning windows in Be...- Biocon chief Kiran Mazumdar-Shaw meets Karnataka Deputy CM DK Shivakumar amidst feudBiocon chief Kiran Mazumdar-Shaw met Karnataka Deputy Chief Minister DK Shivakumar to discuss Bengaluru's growth and innovation. This meeti...
- Bengaluru needs urgent action: Kiran Mazumdar-Shaw says 'our cities need world class infrastructure'Biocon chief Kiran Mazumdar-Shaw reignited the debate on Bengaluru's dire infrastructure after an overseas executive's critical comments. S...
- Bengaluru poor roads under fire once again: Kiran Mazumdar-Shaw asks why roads are so bad; ministers say 'work in progress'Biocon Chairperson Kiran Mazumdar-Shaw has voiced concerns about Bengaluru's poor roads and garbage problem. An overseas visitor questioned...
- Motilal Oswal Financial Services upgrades Biocon to Buy, target price Rs 430Motilal Oswal Financial Services has recommended a buy on Biocon, targeting a price of Rs 430. The company, a leader in the pharmaceuticals...
- Biocon shares surge 5% after USFDA classifies Bengaluru site as VAIBiocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...
- Biocon Biologics gets EU GMP certification from Ireland's HPRAThe company's new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru has received the certif...
- Biocon's arm gets GMP compliance certificate from UK's health regulator MHRA for Bengaluru facilityThe certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, wa...
- Biocon gets establishment inspection report from USFDA for Bengaluru plantThe EIR has been closed with a voluntary action indicated (VAI) classification for the observations, it added. As per the USFDA, a VAI mean...
- Biocon elevates M B Chinappa as CFO of biosimilar subsidiaryM B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been t...
- Biocon subsidiary acquires research facility from Pfizer HealthcareBiocon shares were trading 0.64 per cent higher that their previous close at Rs 226.85 on the BSE.
- Malaysian facility to be commercialised in H2 FY17: BioconInitially, the products from the facility will cater to local markets but they would be taken gradually to global markets, Kiran Mazumdar-S...
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.
- Biocon eyes Rs 100 cr from psoriasis drug in next four yearsThe product would be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...
- Biocon opens integrated R&D centre in BangaloreBiocon today opened an integrated R&D centre here which is aimed at pursuing research on biologics to address unmet medical needs.
- Biocon to invest $161 mn in MalaysiaBiocon will invest $161 million in a facility in Malaysia, joining a number of Indian companies that have chosen to establish facilities in...
- Biocon subsi ties up with Bristol-Myers SquibbIntegrated biotechnology firm Biocon on Wednesday said its subsidiary Syngene has entered into a research partnership with global pharma ma...
- World's first anti-EGFR cancer antibody launchedBiotechnology behemoth Biocon has launched BIOMAb-EGFR, a therapeutic monoclonal antibody-based drug for treating solid tumours of epitheli...
- Biocon PAT at Rs 39 cr in Q1Biocon Limited on Wednesday maintained a profit after tax (PAT) at Rs 39 crore for the quarter ended June 30 in comparision to the same qua...
Load More
